1 Result: Ipsen
Momentum Surge: Elafibranor's PBC Trial Data Boosts Genfit
June 30th, 2023
Ipsen S.A. (OTCMKTS: IPSEY) and Genfit S.A. (Nasdaq: GNFT) have announced positive results from the ELATIVE Phase III trial evaluating elafibranor as a treatment for patients with primary biliary cholangitis (PBC), a rare cholestatic liver disease, w. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Targeting High-Stakes Recruiting Success in 2026
March 25th, 2026Treasury Launches the Artificial Intelligence (AI) Innovation Series
March 23rd, 2026Market Spotlight: Cintas, Ondas, and Chewy Earnings on Deck
March 22nd, 2026Countdown to Earnings: KB Home, Braze, and Comstock Take the Stage
March 22nd, 2026
Member Login